June 06, 2026 — RNews

#immunotherapy — Saturday, June 06, 2026 (1 items)

hot top new

← prev day next day →

0

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. (linkinghub.elsevier.com)

Clowse MEB … Stach C The Lancet 2026-06-06

#clinical trial #immunotherapy #autoimmunity #lupus